Manufacturer
51 recalls in our database name Noven Pharmaceuticals, Inc. as the manufacturing or recalling firm.
Of the 51 recalls from Noven Pharmaceuticals, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 4 (8%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Noven Pharmaceuticals is recalling 182,850 Daytrana patches because they no longer meet release liner removal specifications.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the products no longer meet release liner removal specifications.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because they no longer meet release liner removal specifications.
Noven Pharmaceuticals is recalling 321,900 Daytrana patches because the delivery system no longer meets release liner removal specifications.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal systems because the delivery system failed stability testing for peel force.
Noven Pharmaceuticals is recalling 1,068,600 Daytrana transdermal patches nationwide because the delivery system failed mechanical peel force specifications.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the delivery system failed to meet mechanical peel force specifications.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the delivery system failed to meet mechanical specifications.
Noven Pharmaceuticals is recalling 7,850 boxes of Daytrana (methylphenidate) transdermal patches because the release liner may be difficult to remove.
Noven Pharmaceuticals is recalling specific lots of Daytrana transdermal patches because the release liner may be difficult to remove.
Noven Pharmaceuticals is recalling 2,088 boxes of Daytrana transdermal patches because the release liner may be difficult to remove.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) 30 mg patches due to a defective delivery system that failed mechanical peel force specifications.
Noven Pharmaceuticals is recalling 125,340 Daytrana patches because one lot exceeded the mechanical peel specification. The recall is nationwide.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal patches because prolonged exposure to temperatures outside labeled storage conditions may affect product quality.
Noven Pharmaceuticals is recalling 160,800 Daytrana patches because the adhesive release liner may be difficult to remove.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because out-of-specification results indicate the release liner may be difficult to remove.
Noven Pharmaceuticals is recalling 187,860 Daytrana patches because the release liner may be difficult to remove. The defect affects the ability to apply the patch correctly.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the release liner may be difficult to remove.
Noven Pharmaceuticals is recalling 177,900 Daytrana (methylphenidate) patches because the delivery system may be miscalibrated or defective, potentially affecting the removal of the release liner.
Noven Pharmaceuticals is recalling 231,270 Daytrana patches because the release liner may be difficult to remove.
Noven Pharmaceuticals is recalling 121,530 Daytrana patches because the release liner may be difficult to remove. The defect affects the patch's mechanical peel force.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the delivery system is miscalibrated or defective, potentially affecting drug delivery.
Noven Pharmaceuticals is recalling Daytrana transdermal patches because the release liner may be difficult to remove. This could affect the patient's ability to apply the medication correctly.
Noven Pharmaceuticals is recalling 244,320 Daytrana patches because the delivery system is miscalibrated or defective, making it difficult to remove the release liner.
Noven Pharmaceuticals is recalling 357,510 Daytrana (methylphenidate) patches because the delivery system may be miscalibrated or defective, affecting the ability to remove the release liner.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
NOVEN PHARMACEUTICALS, INC.
Source: Wikidata (Q140588347), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.